| SM ISO690:2012|
FOSA, Olga; ROBU, Maria; POPESCU, Maria. Inhibitorii proteazomali în tratamentul mielomului multiplu. In: Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”. 21-23 octombrie 2020, Chişinău. Chişinău: USMF, 2020, p. 220.
|Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină şi Farmacie „Nicolae Testemiţanu” 2020|
Congresul "Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”" |
Chişinău, Moldova, 21-23 octombrie 2020
Background. Multiple myeloma (MM) take part of monoclonal gamapathies and is characterized by a malignant proliferation of plasmocites. MM represents 1% in the structure of all malignant tumors. The MM morbidity in the Republic of Moldova is 0.6 per 100,000 inhabitants. Objective of the study. To study the efficacy of treatment with proteosomal inhibitors in patients with MM. Material and Methods. The efficacy of the treatment was studied in 59 patients with MM aged 42 to 79 years. Treatment was performed with: bortezomib + cyclophosphamide in 48 patients and bortezomib + thalidomide in 11 patients. Results. The efficacy of the treatment was higher in the patients treated with bortezomib + thalidomide. Clinical-hematological improvement was obtained in 100% of cases. When bortezomib + cyclophosphamide was administered, clinical-haematological improvement was found in only 62.7% of patients. The mean duration of tumor stabilization in patients receiving bortezomib + thalidomide was 13.4 months, and in cases of bortezomib + cyclophosphamide, it was 6.9 months. Conclusion. The combination of bortezomib + thalidomide has better effect then that with cyclophosphamide.
multiple myeloma, treatment, bortezomib,
mielom multiplu, Tratament, bortezomib